BridgeBio Oncology Therapeutics Inc. BBOT · SEC Filings

website

BridgeBio Oncology Therapeutics, Inc., a clinical-stage biotechnology company, engages in the develo...

Price2.3

Market Cap184.26 M

Float72.61 M

CountryUS

SectorHealthcare

ExchangeNASDAQ

Overview Filings Insights Dilution News Transcripts

Search in Documents

Open in Studio Login

TYPE

HEADLINE

FILED AT

TYPE

HEADLINE

FILED AT

TYPE

HEADLINE

FILED AT

TYPE

HEADLINE

FILED AT

Financials

TYPE

HEADLINE

FILED AT

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Aug 11, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

May 12, 2026

10-K

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Mar 5, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Nov 12, 2025

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Aug 1, 2025

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

May 15, 2025

News

TYPE

HEADLINE

FILED AT

8-K

Resignation of BridgeBio Oncology Therapeutics' Chief Medical and Development Officer

Nov 5, 2026

8-K

BridgeBio Oncology Therapeutics Announces New BBO-8520 Clinical Data and Strategic Pipeline Prioritization

Sep 8, 2026

8-K

BridgeBio Oncology Therapeutics Reports Second Quarter 2026 Financial Results and Clinical Progress

Aug 11, 2026

8-K

BridgeBio Oncology Therapeutics, Inc. Announces Board Resignation and 2026 Annual Meeting Results

Jun 22, 2026

8-K

BridgeBio Oncology Therapeutics Reports Q1 2026 Financial Results and Pipeline Progress

May 12, 2026

8-K

BridgeBio Oncology Therapeutics Enters Consulting Agreement with Former CEO Eli Wallace

Apr 29, 2026

Prospectus

TYPE

HEADLINE

FILED AT

424B3